Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Breast 8Gynecologic 4Gastrointestinal 3Other hematologic neoplasm 2Genitourinary 2Endocrine 2NET 1Classical hematology 1CNS 1

Conditions

Anemia, Refractory, with Excess of Blasts 255Myelodysplastic Syndromes 228Leukemia, Myeloid, Acute 228Anemia 212Leukemia 205Precursor Cell Lymphoblastic Leukemia-Lymphoma 168Leukemia, Myelomonocytic, Chronic 145Neoplasms 142Leukemia, Lymphocytic, Chronic, B-Cell 116Myeloproliferative Disorders 114Multiple Myeloma 113Lymphoma, Non-Hodgkin 105Thrombocytopenia 100Lymphoma 98Hodgkin Disease 91Anemia, Refractory 81Venous Thromboembolism 77Congenital Abnormalities 77Anemia, Aplastic 77Primary Myelofibrosis 76Lymphoma, Follicular 73Leukemia, Myeloid, Chronic-Phase 70Blast Crisis 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65Leukemia, Myeloid, Accelerated Phase 64Lymphoma, Mantle-Cell 63Febrile Neutropenia 62Myelodysplastic-Myeloproliferative Diseases 58Hematologic Neoplasms 56Burkitt Lymphoma 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Genetic Predisposition to Disease × Classical hematology × Clear all
NCT01346761 2016-04-14

REACH

University of Utah

Phase NA Completed
1,012 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms, Genetic Predisposition to Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡